3results about How to "Improve dysfunction" patented technology

This invention provides a tin selenide-based nanozyme, comprising tin selenide, with tannic acid and tetravalent cerium ions conjugated on the surface of the tin selenide. The invention also provides a method for preparing the above-mentioned nanozyme, comprising mixing tin selenide with anhydrous ethanol and ultrasonically dispersing the mixture; centrifuging the resulting mixture to obtain a supernatant, further centrifuging the supernatant to obtain a tin selenide nanosheet solution; adding the above tin selenide nanosheet solution and tannic acid solution together to deionized water; subsequently adding cerium nitrate solution and continuing stirring; then adding sodium hydroxide solution to adjust the pH to 8.0; after the reaction is complete, the tin selenide-based nanozyme is obtained. This invention also provides the application of the above-mentioned tin selenide-based nanozyme in the preparation of anti-atherosclerotic drugs. The nanozyme of this invention can effectively alleviate the progression of atherosclerosis.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

The application discloses an anti-wrinkle and anti-photoaging cyclic nonapeptide and application thereof, and the amino acid sequence of the cyclic nonapeptide is: cyclic (arginine-glycine-aspartic acid-serine-tyrosine-lysine-valine-lysine-arginine). The cyclic nonapeptide RGDSYKVKR of the application can significantly increase the content of COL1 in dermal fibroblasts, down-regulate the matrix metalloproteinase genes MMP1 and MMP3, and reduce the aging markers P21 and P16, thereby playing the roles of promoting collagen generation, improving skin elasticity, and lightening skin wrinkles, and having the effects of anti-aging and anti-wrinkle and anti-aging. The cyclic nonapeptide can also significantly increase the content of COL1 in dermal fibroblasts after UV irradiation, reduce the relative expression of the aging markers MMP1, MMP3 and P53 mRNA in the dermal fibroblasts after UV irradiation, and thereby play the role of anti-photoaging.